EUCTR2013-000832-85-IT进行中（未招募）1 期
INTRAMUSCULAR CLODRONATE 200 MG IN THE THERAPY OF HANDS IN PHASE ALGIC OSTEOARTHROSIS - A 6 MONTHS PILOT OPEN STUDY. - ERODE 2
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •° male and female population over 18 years
- •° erosive osteoarthritis diagnosed according to international radiological criteria (at least 2 interphalangeal joints in erosive phase) or primary osteoarthritis of the hands diagnosed according to clinical ACR steroid therapy and DMOADs any suspended for at least three months, including infiltration
- •° phase algic in place to load interphalangeal hands with VAS ? 4 cm/10
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •° erosive osteoarthritis and primary osteoarthritis in inactive phase and not algic
- •° with osteoarthritis of the hands with functional impairment no longer editable (ankylosis)
- •° patients with digestive diseases that contraindicate the use of NSAIDs
- •° suffering from kidney disease, cardiovascular and neoplastic
- •° suffering from systemic diseases and non-severe, not yet stabilized
- •° suffering from psychiatric and / or neurological relevant
- •° suffering from rheumatism, fibromyalgia primary or secondary
- •° syndromes of the upper canalicular
- •° suffering from chronic inflammatory arthropathy albeit temporarily in remission.
- •° those who take illegal drugs and / or alcohol in doses which constitute abuse.
- •° patients with known or suspected hypersensitivity to bisphosphonates
- •° subjects presenting contraindication to the use of NSAIDs
- •° subjects not willing to give their informed consent to participation in the study and patients who do not ensure adequate adherence to the study requires.
- •° patients who are pregnant or nursing, or who have good chance of it during the course of the study.
研究者
相似试验
进行中（未招募）
4 期
ow Dose Intravenous Zoledronate for the Treatment of Post-menopausal Osteoporosis: a prospective open-labeled studypostmenopausal osteoporosis, zoledronate, bone mineral density, fracture, preventionPostmenopausal osteoporosisTCTR20210930001Phramongkutklao hospital36
已完成
不适用
Droperidol OR Midazolam (DORM) for sedation in patients with psychostimulant induced agitatioPsychostimulant induced agitation and deliriumInjuries and Accidents - PoisoningACTRN12607000527460Geoffrey Isbister120
进行中（未招募）
不适用
Administration of the approved drug milrinone via venous access to treat and to prevent vasospasmSAB-induced vasospasmEUCTR2009-016620-32-ATDept. of Neurological Surgery, Medical University of Vienna
进行中（未招募）
不适用
PRETREATMENT WITH HIGH DOSE CLOPIDOGREL FOR REDUCTION OF THROMBOTIC EVENTS AFTER ELECTIVE CORONARY TERRITORY STENTING WITH DRUG ELUTING STENTS: ThePROTECTED Study - The PROTECTED StudyPERCUTANEOUS CORONARY INTERVENTION( USING DRUG ELUTING STENTS)EUCTR2004-000517-19-GBBlackpool Fylde & Wyre Healthcare NHS Trust100
进行中（未招募）
不适用
EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASEOsteoporosis in patients affected by Parkinson's disaease at the stages 1-2-3-4 following Hoehn and Yahr criteriaMedDRA version: 14.1Level: SOCClassification code 10028395Term: Musculoskeletal and connective tissue disordersSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-018904-94-ITFONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE